CN105801701B - 一种pcsk9抗体的重链和轻链可变区及其应用 - Google Patents
一种pcsk9抗体的重链和轻链可变区及其应用 Download PDFInfo
- Publication number
- CN105801701B CN105801701B CN201610191117.1A CN201610191117A CN105801701B CN 105801701 B CN105801701 B CN 105801701B CN 201610191117 A CN201610191117 A CN 201610191117A CN 105801701 B CN105801701 B CN 105801701B
- Authority
- CN
- China
- Prior art keywords
- pcsk9
- seq
- antibody
- heavy chain
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 title claims abstract description 47
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 title claims abstract description 47
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims abstract 2
- 230000014509 gene expression Effects 0.000 claims description 9
- 238000005516 engineering process Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 7
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000001900 immune effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 210000004408 hybridoma Anatomy 0.000 description 11
- 239000007853 buffer solution Substances 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000008157 ELISA kit Methods 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 201000000050 myeloid neoplasm Diseases 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 108010001831 LDL receptors Proteins 0.000 description 2
- 102000000853 LDL receptors Human genes 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108090000787 Subtilisin Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 101001051093 Homo sapiens Low-density lipoprotein receptor Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020961 Hypocholesterolaemia Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710172072 Kexin Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100135848 Mus musculus Pcsk9 gene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150094724 PCSK9 gene Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010044159 Proprotein Convertases Proteins 0.000 description 1
- 102000006437 Proprotein Convertases Human genes 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610191117.1A CN105801701B (zh) | 2016-03-31 | 2016-03-31 | 一种pcsk9抗体的重链和轻链可变区及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610191117.1A CN105801701B (zh) | 2016-03-31 | 2016-03-31 | 一种pcsk9抗体的重链和轻链可变区及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105801701A CN105801701A (zh) | 2016-07-27 |
CN105801701B true CN105801701B (zh) | 2019-03-29 |
Family
ID=56455106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610191117.1A Expired - Fee Related CN105801701B (zh) | 2016-03-31 | 2016-03-31 | 一种pcsk9抗体的重链和轻链可变区及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105801701B (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3515949A4 (en) * | 2016-09-20 | 2020-10-28 | Wuxi Biologics Ireland Limited. | NEW ANTI-PCSK9 ANTIBODIES |
TW201825524A (zh) * | 2016-09-20 | 2018-07-16 | 中國大陸商上海藥明生物技術有限公司 | 新型抗-pcsk9抗體 |
EP3515950A4 (en) * | 2016-09-20 | 2020-10-28 | Wuxi Biologics Ireland Limited. | NEW ANTI-PCSK9 ANTIBODIES |
CN108239150A (zh) * | 2016-12-24 | 2018-07-03 | 信达生物制药(苏州)有限公司 | 抗pcsk9抗体及其用途 |
EP4063506A4 (en) * | 2019-09-19 | 2023-09-06 | Innovent Biologics (Suzhou) Co., Ltd. | METHOD FOR PREVENTING OR TREATING CHOLESTEROL-RELATED DISEASES USING AN ANTI-PCSK9 ANTIBODY |
WO2024002357A1 (zh) * | 2022-06-30 | 2024-01-04 | 康融东方(广东)医药有限公司 | 抗pcsk9抗体的制剂及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101636179A (zh) * | 2006-11-07 | 2010-01-27 | 默克公司 | Pcsk9拮抗剂 |
CN102066420A (zh) * | 2008-02-07 | 2011-05-18 | 默沙东公司 | 1d05 pcsk9拮抗剂 |
CN102652139A (zh) * | 2009-12-11 | 2012-08-29 | Irm责任有限公司 | Pcsk9拮抗剂 |
CN103261230A (zh) * | 2010-12-22 | 2013-08-21 | 霍夫曼-拉罗奇有限公司 | 抗pcsk9抗体及使用方法 |
CN103562227A (zh) * | 2011-02-11 | 2014-02-05 | Irm责任有限公司 | Pcsk9拮抗剂 |
CN104540852A (zh) * | 2012-08-13 | 2015-04-22 | 瑞泽恩制药公司 | 具有pH-依赖性结合特性的抗-PCSK9抗体 |
CN104861071A (zh) * | 2015-04-27 | 2015-08-26 | 南京师范大学 | 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 |
CN105001336A (zh) * | 2014-04-18 | 2015-10-28 | 上海复旦张江生物医药股份有限公司 | Pcsk9拮抗剂 |
-
2016
- 2016-03-31 CN CN201610191117.1A patent/CN105801701B/zh not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101636179A (zh) * | 2006-11-07 | 2010-01-27 | 默克公司 | Pcsk9拮抗剂 |
CN102066420A (zh) * | 2008-02-07 | 2011-05-18 | 默沙东公司 | 1d05 pcsk9拮抗剂 |
CN102652139A (zh) * | 2009-12-11 | 2012-08-29 | Irm责任有限公司 | Pcsk9拮抗剂 |
CN103261230A (zh) * | 2010-12-22 | 2013-08-21 | 霍夫曼-拉罗奇有限公司 | 抗pcsk9抗体及使用方法 |
CN103562227A (zh) * | 2011-02-11 | 2014-02-05 | Irm责任有限公司 | Pcsk9拮抗剂 |
CN104540852A (zh) * | 2012-08-13 | 2015-04-22 | 瑞泽恩制药公司 | 具有pH-依赖性结合特性的抗-PCSK9抗体 |
CN105001336A (zh) * | 2014-04-18 | 2015-10-28 | 上海复旦张江生物医药股份有限公司 | Pcsk9拮抗剂 |
CN104861071A (zh) * | 2015-04-27 | 2015-08-26 | 南京师范大学 | 针对pcsk9的全人源单克隆抗体的可变区基因及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105801701A (zh) | 2016-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105801701B (zh) | 一种pcsk9抗体的重链和轻链可变区及其应用 | |
US11512129B2 (en) | TIGIT antibody, antigen-binding fragment thereof, and medical use thereof | |
US20230160105A1 (en) | Generation of binding molecules | |
CN109937212B (zh) | B7-h3抗体、其抗原结合片段及其医药用途 | |
CN109862784A (zh) | 产生经修饰的仅有重链的抗体的转基因非人动物 | |
CN108472349A (zh) | Lag-3抗体、其抗原结合片段及其医药用途 | |
CN101851291B (zh) | 一种抗人baff单克隆抗体的重链和轻链可变区 | |
CN111744013B (zh) | 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合 | |
CN109206514B (zh) | Tslp单克隆抗体及其制备方法和应用 | |
CN103936853B (zh) | 一种检测tim-3试剂盒及其使用方法 | |
CN109734813A (zh) | 一种嵌合抗原受体及其应用 | |
JPH08500487A (ja) | L鎖欠落免疫グロブリン | |
CN105820250B (zh) | 一种抗basigin人源化抗体及其应用 | |
CN109776678A (zh) | 一种人源化pd-l1单克隆抗体、其制备方法和应用 | |
CN112500485B (zh) | 一种抗b7-h3抗体及其应用 | |
CA2476773C (en) | Monoclonal antibodies against extracellular loops of c5ar | |
CN113151186B (zh) | 抗人cd271的单克隆抗体及用途 | |
CN111533805A (zh) | 一种抗癌胚抗原的高亲和力纳米抗体及其应用 | |
CN107207581A (zh) | 用于制备优化的治疗分子的方法 | |
CN110872353B (zh) | 特异性结合pcsk9抗原的纳米抗体及其制备方法和应用 | |
CN114685666A (zh) | 抗间皮素纳米抗体及其应用 | |
CN106543285B (zh) | 抗Ttyh1单克隆抗体及其应用 | |
CN114478783B (zh) | 一种eno2单克隆抗体及其制备方法和应用 | |
CN111349157B (zh) | 钙粘附蛋白6的单克隆抗体及其应用 | |
CN116333149A (zh) | 一种结合pcsk9抗原的单域抗体及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170922 Address after: 100084 Haidian District Tsinghua University Park, Tsinghua University, Beijing Institute of science and research building, floor B801-016, No. eight Applicant after: BEIJING XINSHENGYUAN BIOMEDICAL TECHNOLOGY CO.,LTD. Address before: 100022 Beijing city Chaoyang District South Mill Road No. 37 room 1701-1703 (Beitang Huateng centralized Office District No. 179224) Applicant before: BEIJING ZHONGKE LIJUN BIOMEDICAL TECHNOLOGY Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190131 Address after: 065500 New Industry Demonstration Park, Gu'an County, Langfang City, Hebei Province Applicant after: HEBEI RENBO TECHNOLOGY Co.,Ltd. Address before: 100084 No. B801-016, 8th Floor, Tsinghua University Research Building, Tsinghua Garden, Haidian District, Beijing Applicant before: BEIJING XINSHENGYUAN BIOMEDICAL TECHNOLOGY CO.,LTD. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201204 Address after: Hou Ji Zhen Xi Zhang Lou Cun, Cao County, Heze City, Shandong Province Patentee after: Caoxian Hengzhe Handicraft Co.,Ltd. Address before: 065500 New Industry Demonstration Park, Gu'an County, Langfang City, Hebei Province Patentee before: HEBEI RENBO TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190329 |
|
CF01 | Termination of patent right due to non-payment of annual fee |